Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
RRx-001 has shown promise as a novel cancer therapeutic agent. The disposition of RRx-001 was evaluated in vitro and after intravenous administration to rats. At both 24 and 168 h after a single intravenous administration of ¹⁴C-RRx-001 (10 mg/kg), the majority of radiolabel was in the blood. The recovery of label in excreta was quite low, but the major route of radiolabel excretion was via the kidney, with approximately 26% in the urine by the first 8 h and decreasing amounts in all subsequent collections to a total of 36.3% by 168 h. The partitioning of total radioactivity in red blood cells (RBCs) and plasma was determined after in vitro addition to human, rat, dog, and monkey whole blood at 1 and 20 μM. In rat, at 30 min, approximately 75% of the radioactivity is associated with RBCs and 25% with plasma. In human, at 30 min, approximately 25% of the radioactivity is associated with RBCs and 75% with plasma. Analysis by liquid chromatography/radiodetection/mass spectrometry showed that ¹⁴C-RRx-001 reacted rapidly with whole blood to give four major soluble metabolites: the GSH and Cys adducts of RRx-001 (M1 and M2) and the corresponding mononitro GSH and Cys adducts (M3 and M4). Human Hb was incubated with cold RRx-001 in buffer, and a standard proteomics protocol was used to separate and identify the tryptic peptides. Standard peptide collision-induced fragment ions supported the structure of the peptide GTFATLSELHCDK with the alkylation on the Cys-93 locus of the Hb β chain.
RadioRx Inc., Mountain View, California, USA.
Jan
J
Scicinski
Bryan
B
Oronsky
Michael
M
Taylor
Gang
G
Luo
Timothy
T
Musick
Joseph
J
Marini
Christopher M
CM
Adams
William L
WL
Fitch
D000478:Alkylation; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D001384:Azetidines / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D001711:Biotransformation; D002853:Chromatography, Liquid; D003545:Cysteine; D004285:Dogs; D004912:Erythrocytes / Q000378:metabolism; D000882:Haplorhini; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007275:Injections, Intravenous; D007668:Kidney / Q000378:metabolism; D008297:Male; D008657:Metabolic Clearance Rate; D009574:Nitro Compounds / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D010449:Peptide Mapping; D011485:Protein Binding; D040901:Proteomics / Q000379:methods; D051381:Rats; D017208:Rats, Wistar; D013438:Sulfhydryl Compounds / Q000378:metabolism; D053719:Tandem Mass Spectrometry; D014018:Tissue Distribution; D055544:beta-Globins / Q000378:metabolism
D000970:Antineoplastic Agents; D001384:Azetidines; D006454:Hemoglobins; D009574:Nitro Compounds; C577469:RRx-001; D013438:Sulfhydryl Compounds; D055544:beta-Globins; D003545:Cysteine